Guest column

Houston expert: Now is the time to diversify your workforce in the name of innovation

As Women's History Month wraps up, it's time to reflect on the enabling diversity and inclusion in the workplace as a driver of innovation. Photo via Getty Images

Pop quiz: What's the best way to introduce and nurture a culture of innovation in your organization?

  1. Give all employees a VR headset
  2. Mandate every team leader offer one new idea per quarter
  3. Add the word "innovate" to the organization's mission statement
  4. Actively recruit, hire and support a more diverse workforce

If you didn't answer D, you have some research to do. A trove of recent research shows an undeniable link between workforce diversity and innovation, not to mention better overall results. From McKinsey to the Boston Consulting Group to HBR the data keeps coming.

For instance, Deloitte found organizations with more inclusive cultures are both significantly more innovative and twice as likely to meet or exceed financial targets than their counterparts. My own company, Sodexo, commissioned a study that found gender-balanced teams contribute to better outcomes across the board, including innovation.

Beyond the hard evidence, pure common sense tells us when we open our doors to people with different perspectives and life experiences, we also welcome new ideas. Diverse teams encourage diverse thinking, new solutions and agile implementation. There's a reason that Great Place to Work calls diverse and inclusive teams "the engines of innovation."

At the same time, innovation has become essential in our current economic climate. If this past year has taught us anything, it's that we need to be nimble and ready to think differently at a moment's notice.

As we close out another Women's History Month, we are rounding out a year that has been a collective setback for women in the workplace, in particular. Millions of women have left the labor market during the global pandemic and it's unclear how many will return and what professional repercussions they will face.

This comes as our industry was already woefully lacking gender parity. According to a 2019 Catalyst study, there were fewer women in oil and gas than almost any other major industry. The group found women accounted for only 22 percent of employees, 17 percent of senior level roles and one percent of top leadership.

In other words, the pandemic has given us even more work to do — both in recruiting women and a more diverse employee base in general. We need to do so if we are to transform into the future-oriented industry our customers need us to be.

The news is not all doom and gloom, however. An eye-opening McKinsey report about our industry, "Oil and gas after COVID-19" argues that the global pandemic "will be a catalytic moment and accelerate permanent shifts in the industry's ecosystem, with new future opportunities." The authors lay out several potential avenues for successful organizations, including the ability to "create the organization of the future," by recruiting a new blend of talent that will bring innovative ideas.

This is a watershed moment to rethink how we recruit and hire. We can look more broadly at what we look for and from which fields we recruit. We can consider how different ideas and perspectives can help us forge paths toward our future.

We have the data to fuel the changes we need. We also have the data to offer us the cautionary tale of not changing. As the McKinsey report put it: "The opportunity to lead has never been better—separation between market leaders and laggards will be increasingly sharp."

------

Stephanie Hertzog is the CEO of Houston-based Sodexo Energy & Resources North America.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted